Plonmarlimab is under clinical development by I-Mab and currently in Phase III for Cytokine Release Syndrome (Cytokine Storm). According to GlobalData, Phase III drugs for Cytokine Release Syndrome (Cytokine Storm) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Plonmarlimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Plonmarlimab (TJM-2) is under development for the treatment of rheumatoid arthritis, cytokine storm associated with coronavirus disease (COVID-19) and neuroinflammation. It is administered by intravenous route as an infusion. The therapeutic candidate is a humanized IgG1 monoclonal antibody which acts by targeting GMCSF.
I-Mab is a biopharmaceutical company. It develops transformational medicines focused on the therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. The company collaborates with biotechnology companies, CROs, and CMOs to advance the clinical development of its pipeline assets and out-licensing opportunities. It operates in China, Hong Kong, and the US. I-Mab is headquartered in Shanghai, China.
For a complete picture of Plonmarlimab’s drug-specific PTSR and LoA scores, buy the report here.